A new treatment for severe liver disease is being tested in humans for the first time. Resolution Therapeutics has started its EMERALD study, which is testing RTX001—a first-of-its-kind therapy designed to help repair liver damage. The first patient has safely received the treatment, and the study is now enrolling more participants in the UK and Spain. RTX001 is the first engineered macrophage therapy to be tested in people with advanced liver fibrosis, a condition where the liver becomes scarred and stops working properly. The study will check if the treatment is safe and effective in up to 25 patients who have recovered from severe liver complications. The first patient was treated at the Royal Infirmary of Edinburgh. Experts are hopeful that this new therapy could offer a much-needed treatment option for people with end-stage liver disease, a condition with very few effective treatments. Results from the study are expected in 2026.